Cellectis (NASDAQ:CLLS) Research Coverage Started at StockNews.com
StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a report released on Sunday morning. The brokerage issued a hold rating on the biotechnology company’s stock. Other research analysts also recently issued research reports about the stock. JMP Securities reaffirmed a market outperform rating and set a $6.00 price objective on shares […]
More Stories
Wall Street Zen Downgrades ATRenew (NYSE:RERE) to Buy
ATRenew (NYSE:RERE – Get Free Report) was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a...
Wall Street Zen Upgrades John Wiley & Sons (NYSE:WLY) to “Strong-Buy”
John Wiley & Sons (NYSE:WLY – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from...
Wall Street Zen Downgrades Unisys (NYSE:UIS) to Hold
Unisys (NYSE:UIS – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “buy” rating to...
Wall Street Zen Upgrades Masco (NYSE:MAS) to “Hold”
Masco (NYSE:MAS – Get Free Report) was upgraded by analysts at Wall Street Zen from a “sell” rating to a...
Sphere Entertainment (NYSE:SPHR) Stock Rating Lowered by Wall Street Zen
Sphere Entertainment (NYSE:SPHR – Get Free Report) was downgraded by analysts at Wall Street Zen from a “hold” rating to...
PHX Minerals (NYSE:PHX) Raised to “Buy” at Wall Street Zen
PHX Minerals (NYSE:PHX – Get Free Report) was upgraded by research analysts at Wall Street Zen to a “buy” rating...